Abstract：
BACKGROUND: Endovascular treatment of wide neck aneurysms remains complicated with a determined and continuous technological effort towards treatment options that can offer safer and efficacious outcomes. The Woven Endobridge device was introduced in 2010 and has become a mainstay endovascular treatment for wide neck and large intracranial aneurysms. A recent review of the Woven Endobridge Clinical Assessment of Intrasaccular Aneurysm Therapy (WEBCAST) and WEBCAST2 trials and the five-year follow-up of patients was published. Our aim is to demonstrate real-life experience of aneurysms and patients treated with Woven Endobridge from a large high-volume specialist centre.
METHODS: A retrospective review was performed of patients treated with Woven Endobridge from March 2013 to March 2018. Primary efficacy outcomes were defined as per Raymond-Roy Occlusion Criteria (RROC) resulting in long-term complete occlusion (RROC1) and adequate occlusion (RROC1 and RROC2). Primary Safety outcomes were defined as procedure-related morbidity, rate of re-bleeding and rate of re-treatment.
RESULTS: Seventy-nine aneurysms were treated during the five-year period. Adequate aneurysm occlusion (RROC1 and RROC2) achieved was 81%. Retreatment was required in 18% of patients (14/79). Greater retreatment rate was demonstrated in partially thrombosed aneurysms, aneurysms with larger neck and dome diameter and dome heights.
CONCLUSIONS: Woven Endobridge treatment of wide-neck intracranial aneurysms offers a safe and efficacious outcome. This large UK single-centre experience demonstrates congruity with recent five-year outcomes of WEBCAST and WEBCAST2 trials.
METHODS: A retrospective review was performed of patients treated with Woven Endobridge from March 2013 to March 2018. Primary efficacy outcomes were defined as per Raymond-Roy Occlusion Criteria (RROC) resulting in long-term complete occlusion (RROC1) and adequate occlusion (RROC1 and RROC2). Primary Safety outcomes were defined as procedure-related morbidity, rate of re-bleeding and rate of re-treatment.
RESULTS: Seventy-nine aneurysms were treated during the five-year period. Adequate aneurysm occlusion (RROC1 and RROC2) achieved was 81%. Retreatment was required in 18% of patients (14/79). Greater retreatment rate was demonstrated in partially thrombosed aneurysms, aneurysms with larger neck and dome diameter and dome heights.
CONCLUSIONS: Woven Endobridge treatment of wide-neck intracranial aneurysms offers a safe and efficacious outcome. This large UK single-centre experience demonstrates congruity with recent five-year outcomes of WEBCAST and WEBCAST2 trials.
摘要：
背景：宽颈动脉瘤的血管内治疗仍然是复杂的，需要坚定和持续的技术努力，以提供更安全和有效的治疗方案。WovenEndobridge装置于2010年推出，已成为广泛颈部和大型颅内动脉瘤的主要血管内治疗方法。最近发表了一项关于囊内动脉瘤治疗（WEBCAST）和WEBCAST2试验的WovenEndobridge临床评估以及对患者的五年随访的综述。我们的目标是展示来自大型高容量专家中心的动脉瘤和使用WovenEndobridge治疗的患者的真实体验。
方法：对2013年3月至2018年3月期间接受WovenEndobridge治疗的患者进行回顾性分析。根据Raymond-Roy闭塞标准（RROC）定义主要疗效结果，导致长期完全闭塞（RROC1）和充分闭塞（RROC1和RROC2）。主要安全性结果定义为与手术相关的发病率，再出血率和再治疗率。
结果：在五年期间治疗了79个动脉瘤。达到的足够动脉瘤闭塞（RROC1和RROC2）为81％。18％的患者需要重新治疗（14/79）。在部分血栓形成的动脉瘤中显示出更高的再治疗率，具有较大颈部和圆顶直径和圆顶高度的动脉瘤。
结论：WovenEndobridge治疗颅内宽颈动脉瘤可提供安全有效的结果。这个大型英国单中心的经验证明了与WEBCAST和WEBCAST2试验最近五年的结果一致。
方法：对2013年3月至2018年3月期间接受WovenEndobridge治疗的患者进行回顾性分析。根据Raymond-Roy闭塞标准（RROC）定义主要疗效结果，导致长期完全闭塞（RROC1）和充分闭塞（RROC1和RROC2）。主要安全性结果定义为与手术相关的发病率，再出血率和再治疗率。
结果：在五年期间治疗了79个动脉瘤。达到的足够动脉瘤闭塞（RROC1和RROC2）为81％。18％的患者需要重新治疗（14/79）。在部分血栓形成的动脉瘤中显示出更高的再治疗率，具有较大颈部和圆顶直径和圆顶高度的动脉瘤。
结论：WovenEndobridge治疗颅内宽颈动脉瘤可提供安全有效的结果。这个大型英国单中心的经验证明了与WEBCAST和WEBCAST2试验最近五年的结果一致。
